Phase 1 Study OF CDC-501 in Patients With Solid Tumors

Celgene

Status and phase

Completed

Phase 1

Conditions

Neoplasms

Treatments

Drug: Lenalidomide

Study type

Interventional

Funder types

Industry

Identifiers

NCT00046735

CC-5013-ST-003

Details and patient eligibility

About

To identify the maximum tolerated dose (MTD) and safety of CDC-501 when given in a 6-week cycle in patients with solid tumors that are refractory after standard treatment.

Full description

Identify the maximum tolerated dose (MTD) and safety of CDC-501 when given in a 6-week cycle in patients with solid tumors that are refractory after standard treatment

Enrollment

24 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Patient must understand and voluntarily sign an informed consent document.
Age 18 years at the time of signing Informed Consent
Histologically or cytologically documented solid tumors that are refractory to standard/conventional therapy or for which no standard/conventional therapy exists.
Patients must have at least one measurable or non-measurable lesion according to the RECIST Criteria (Appendix I).
Patient has an ECOG (Zubrod) performance status of ≤ 2.
Approximate life expectancy greater than 3 months.
Laboratory tests within these ranges:
- Absolute neutrophil count ≥ 1,500/μlL
- Platelet count ≥100,000/μL
- Serum creatinine ≤1.5 mg/dL
- Total bilirubin ≤1.5 mg/dL
- AST (SGOT)/ALT(SGPT) ≤ 2 x upper limit of normal (ULN) or ≤ 5 x ULN if hepatic metastases present
The following prior treatments are allowable under this protocol:
Radiation, if discontinued at least 4 weeks prior to treatment under this protocol Chemotherapy, if discontinued at least 4 weeks prior to treatment under this protocol, and at least 6 weeks prior to treatment under this protocol for prior nitrosurea or mitomycin-C treatment
Hormonal therapy for cancer, if discontinued at least 4 weeks prior to treatment under this protocol
Other investigational drugs, if discontinued at least 4 weeks prior to treatment under this protocol
Surgery, if minor surgery occurred at least 2 weeks prior to treatment under this protocol, or at least 4 weeks since major surgery
Patient must be able to adhere to the study visit schedule and other protocol requirements.
Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test within 7 days prior to baseline. In addition, sexually active WCBP must agree to use adequate contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner).

Exclusion Criteria

Myocardial infarction within the previous 6 months, unstable angina,symptomatic congestive heart failure, or other significant uncontrolled cardiac arrhythmia.
Cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis or other significant thromboembolic event in the previous 6 months.
Active infection, including known human immunodeficiency virus (HIV) positivity or acquired-immunodeficiency-syndrome (AIDS)-related illness.
CNS metastases, unless controlled by previous radiation and the patient is neurologically stable.
Any serious medical condition, laboratory abnormality or psychiatric illness that would prevent the patient from signing the informed consent or limit survival to less than 3 months.
Pregnant or nursing females.Female patients of childbearing potential who are unwilling to use reliable contraceptive methods.
Any condition, including the presence of laboratory abnormalities, which in the opinion of the Investigator places the patient at unacceptable risk if he/she were to participate in the study.